[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microvascular-coronary-artery-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microvascular-coronary-artery-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,83,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100640946","impact-of-hyperemic-state-on-angio-imr-performance-100640946",false,"NCT07613996","Impact of Hyperemic State on Angio-IMR Performance","The Impact of Hyperemic State on the Performance of Angiography Derived Indices in Assessing Coronary Microvascular Disease","Inclusion Criteria:\n\n* Stable angina or suspected coronary heart disease.\n* Scheduled for coronary angiography and physiological assessment.\n* Target vessel with stenosis \\\u003C 50% or 50%-90% with fractional flow reserve (FFR) \\> 0.80.\n* Provided informed consent.\n\nExclusion Criteria:\n\n* Hemodynamic instability (acute myocardial infarction, cardiogenic shock, severe arrhythmia).\n* Contraindications to angiography (e.g., end-stage renal disease).\n* Contraindications to adenosine (e.g., severe asthma, high-degree atrial-ventricular block).\n* Life expectancy \\\u003C 1 year or pregnancy.\n* Target vessel unsuitable for wire operation (left main lesion, severe tortuosity) or stenosis \\> 90%.","ALL","18 Years",{"count":19,"type":20},192,"ESTIMATED","1 Day","OBSERVATIONAL","The goal of this observational study is to evaluate the diagnostic performance of angiography-derived microcirculatory indices (Angio-IMR) in assessing patients with stable angina or suspected coronary artery disease. The main questions it aims to answer are:\n\nHow do the numerical values of Angio-IMR from five different software vendors change across three physiological states (resting, sub-hyperemia induced by nitroglycerin, and maximal hyperemia induced by adenosine)? Which physiological state and software algorithm provide the highest diagnostic accuracy (Area Under the Curve, AUC) for diagnosing Coronary Microvascular Disease (CMD) when compared to the gold standard wire-based IMR? Researchers will compare the Angio-IMR results calculated under the three different physiological conditions within the same patient to see how the hyperemic state impacts the performance and consistency of these non-invasive indices.\n\nParticipants will:\n\nUndergo standard-of-care coronary angiography and physiological assessment using a pressure wire for index of microvascular resistance (Wire-IMR) as part of their clinical management.\n\nHave their angiographic images captured at three specific time points: at rest, after intracoronary nitroglycerin, and during adenosine-induced maximal hyperemia.\n\nAllow their de-identified imaging and clinical data to be analyzed by an independent core laboratory using five different Angio-IMR software platforms to evaluate microvascular function.",[25,26],"Coronary Artery Disease","Microvascular Coronary Artery Disease",[28,29,30,31],"Coronary Physiology","Computational Fluid Dynamics","Index of Microcirculatory Resistance","Angiography-Derived Indices","RECRUITING","2026-05-21",{"date":35,"type":36},"2026-05-29","ACTUAL",{"date":38,"type":36},"2026-05-04",{"date":40,"type":20},"2026-12-31",{"name":42,"class":43},"Shanghai Zhongshan Hospital","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100477065","coronary-sinus-reducer-implantation-in-patients-with-ischaemia-and-non-obstructed-coronary-arteries-and-coronary-microvascular-dysfunction-100477065","NCT05492110","Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.","REducing Microvascular Dysfunction in Patients With Angina, Ischaemia and unobstructED coronarY Arteries - a PILOT Study","REMEDY-PILOT","Inclusion Criteria:\n\n1. Age \\>18 years\n2. Ongoing symptomatic angina, CCS Class II-IV, for ≥3 months despite background treatment with at least two anti-anginal drug at the maximal tolerated dose.\n3. Patients willing to consider no change in anti-anginal drug treatment for the duration of their participation in the trial.\n4. Unobstructed coronary arteries with ≤50% epicardial stenoses demonstrated on coronary angiography.\n5. Stress-induced hypoperfusion on CMR (Global MPR ≤ 2.2).\n6. Willingness to comply with the specified follow-up evaluation and to be contactable during the period of the trial.\n7. Understands the nature of the trial procedures and provides written informed consent.\n\nExclusion Criteria:\n\n1. Epicardial CAD in a main coronary artery (stenoses \\>50%, RFR≤0.92 or FFR≤0.80), coronary artery bypass grafting, or myocardial infarction (MI).\n2. Previous PCI within 6 months\n3. PCI with stent insertion for acute MI or chronic total occlusion (CTO)\n4. Abnormal coronary sinus anatomy (tortuosity, aberrant branch, persistent left superior vena cava)\n5. Coronary sinus diameter at site of implant \\\u003C9.5mm or \\>13mm\n6. Mean right atrial pressure \\\u003C15mmHg at time of implantation\n7. Any structural heart disease including left ventricular hypertrophy; cardiomyopathy; severe valvular heart disease; previous valve replacement; myocardial bridge on angiography; LVEF\\\u003C45% by CMR.\n8. Clinically or angiographically diagnosed coronary vasospasm\n9. Previous hospitalisation for decompensated heart failure\n10. Pacemaker or defibrillator electrode in the right atrium, right ventricle or coronary sinus\n11. Documented arrhythmia requiring planned implantation of a permanent pacemaker or defibrillator\n12. Chronic kidney disease (creatinine \\>200 micromol\u002FL; established on renal replacement therapy; functioning renal transplant)\n13. Haemoglobin \\\u003C80g\u002FL\n14. Contraindications to receiving dual antiplatelet therapy\n15. Severe chronic obstructive pulmonary disease (FEV1 \\\u003C55% predicted)\n16. Moribund patients with life expectancy \\\u003C 1year\n17. Known allergy to nickel or steel\n18. Current enrolment in another investigational device or drug trial\n19. Contraindications to CMR or receiving intravenous adenosine\n20. Pregnancy",{"count":54,"type":20},54,"INTERVENTIONAL",[57],"NA","To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic substudy investigate the physiological responses in the coronary microcirculation responsible for changes in myocardial perfusion.",[60,61,26,62,63],"Refractory Angina","Microvascular Angina","Coronary Disease","Angina Pectoris",[65,66,67,68,69,70,71,72],"Angina pectoris","Refractory angina","Microvascular angina","Coronary microvascular dysfunction","Coronary sinus reducer","Chest pain","Coronary disease","Myocardial ischaemia","2025-03-31",{"date":75,"type":36},"2025-04-03",{"date":77,"type":36},"2023-04-17",{"date":79,"type":20},"2026-03-06",{"name":81,"class":43},"Imperial College London",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":55,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":82},"100536826","study-comparing-two-administration-pathways-for-adenosine-during-microvascular-function-assessment-100536826","NCT06269874","Study Comparing Two Administration Pathways for Adenosine During Microvascular Function Assessment","A Single-centric, ProspectivE, Randomized Controlled Study Comparing Two Administration Pathways for Adenosine During Invasive Assessment of Microvascular Function in Patients With ANOCA.","ASPERA-ANOCA","Inclusion Criteria:\n\n* Chronic coronary syndrome (including patients with anginal equivalents).\n* Indication to cardiac catheterization;\n* Indication to the assessment of microvascular function (note: patients will be asked for participation and consented prior to the first measurement of microvascular function, which will be conducted as per clinical indication)\n* Willingness to participate and ability to understand, read and sign the informed consent\n* Age\\>18 years\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Bronchial asthma, COPD (chronic obstructive pulmonary disease)\n* Secondary or tertiary atrioventricular block without prior pacemaker implantation\n* Previous CABG (coronary artery bypass graft) with patent grafts to the left anterior descending coronary\n* Epicardial coronary disease (FFR \\\u003C0.80 with evidence of a focal stenosis) in the left anterior descending territory\n* Inability to provide informed consent",{"count":92,"type":20},40,[57],"The aim of this study is to investigate the agreement and reproducibility between intravenous and intracoronary adenosine administration during invasive assessment of microvascular function.\n\nGoals of this study are:\n\n1. Agreement and reproducibility between intravenous and intracoronary adenosine administration in the IMR (Index of microvascular resistance) value.\n2. Agreement and reproducibility of FFR(fractional flow reserve), CFR (coronary flow reserve), MRR (microvascular resistance reserve), RRR (resistive reserve ratio) and reproducibility of each of these as compared with CFRabs (absolute coronary flow).\n3. Time required for IMR measurements",[26],[97,98,99],"adenosine","coronary microvascular assessment","microvascular disease","NOT_YET_RECRUITING","2024-10-06",{"date":103,"type":36},"2024-10-08",{"date":105,"type":20},"2027-03-02",{"date":107,"type":20},"2027-08-31",{"name":109,"class":43},"Johannes Gutenberg University Mainz",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":82},"100426016","myocardial-ischemia-without-obstructive-coronary-stenoses-100426016","NCT04827498","Myocardial Ischemia Without Obstructive Coronary Stenoses","Myocardial Ischemia Without Obstructive Coronary Stenoses: A Prospective Observational Study With Invasive Coronary Pressure and Flow Measurements and Endothelial Function Test","Inclusion Criteria:\n\n* Written informed consent available.\n* Age ≥ 18 years.\n* Patient eligible for invasive physiological assessment with adenosine and \u002F or acetylcholine.\n\nExclusion Criteria:\n\n* Hemodynamic instability.\n* Anticipated technical issues for physiology wire measurements.\n* Culprit vessel of acute coronary syndrome\n* Contraindications for adenosine administration.\n* Contraindications for acetylcholine test.\n* Reduced life expectancy (less than 1 year).",{"count":118,"type":20},600,"Coronary-related myocardial ischemia can result from obstructive epicardial stenosis or non-obstructive causes including coronary microcirculatory dysfunction and vasomotor disorders. This prospective study has been created in order to provide knowledge in the field of non-obstructive coronary artery disease.",[121,122,26,123,124],"Myocardial Ischemia","Non-Obstructive Coronary Atherosclerosis","Vasospastic Angina","Myocardial Bridging","2021-04-23",{"date":127,"type":36},"2021-04-26",{"date":129,"type":36},"2017-11-08",{"date":131,"type":20},"2030-12-31",{"name":133,"class":43},"Hospital San Carlos, Madrid"]